ProNAi Therapeutics is a private company dedicated to developing and commercializing a new class of therapies based on its proprietary DNAi platform for patients with cancer and hematological diseases. ProNAi’s lead DNAi product candidate, PNT2258, is specifically designed to treat cancers that overexpress the BCL2, an important and validated oncogene known to be dysregulated in many types of cancer. To date, 35 patients have been treated with PNT2258 in a Phase I and a pilot Phase II trial, with promising efficacy and safety results reported. ProNAi is pursuing a multi-faceted clinical development strategy designed to efficiently achieve regulatory approval and maximize the commercial opportunity of PNT2258. ProNAi recently enrolled the first patient in the “Wolverine” Phase II study evaluating PNT2258 in relapsed or refractory diffuse large B-cell lymphoma (DLBCL). For more information, please visit www.pronai.com.
View Top Employees from ProNAi Therapeutics| Website | http://www.pronai.com |
| Ticker | SRRA |
| Revenue | $15 million |
| Employees | 7 (4 on RocketReach) |
| Founded | 2004 |
| Phone | (650) 376-8679 |
| Technologies | |
| Industry | Biotechnology, Drug Manufacturing & Research, Hematology, Pharmaceuticals, Drug Development, Healthcare, Oncology, Drug Discovery |
| Competitors | BioLineRx, Corbus Pharmaceuticals, G1 Therapeutics, Inc., Idera Pharmaceuticals, ORIC Pharmaceuticals Inc. |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 32541 Companies, NAICS Code 3254 Companies |
Looking for a particular ProNAi Therapeutics employee's phone or email?
ProNAi Therapeutics Questions
The ProNAi Therapeutics annual revenue was $15 million in 2024.
4 people are employed at ProNAi Therapeutics.
ProNAi Therapeutics is based in Vancouver, British Columbia.
The NAICS codes for ProNAi Therapeutics are [325, 32, 32541, 3254].
The SIC codes for ProNAi Therapeutics are [283, 28].
Related Companies
